Suven Pharmaceuticals acquires 56% stake in NJ Bio

21 Dec 2024 Evaluate

Suven Pharmaceuticals has acquired 56% equity share capital of NJ Bio, Inc., at an aggregate consideration of $64.4 million, which includes $15 million of primary equity infusion into the NJ Bio. Therefore, the acquisition of 56% equity share capital of NJ Bio by the company has been completed on December 20, 2024.

Suven Pharmaceuticals is India’s leading technology-focused CDMO, offering integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators.


Suven Pharma Share Price

1180.90 -37.40 (-3.07%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.